Salute e Benessere

OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of…

$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ count As first announced on August 25, 2025, the acquisition combines OrganOx’s pioneering organ perfusion technology with Terumo’s global scale and expertise in medical innovation. “The global need for donor organs remains urgent, with thousands of patients each year dying while waiting for a transplant or facing the risk of a failed transplant,” said Craig...
Nasdaq GlobeNewswire
30/10/2025

Cambridge Atomworks is delighted to announce the appointment of Mr Alistair…

Ian Farnan, CEO, said, “We are excited to welcome someone with Alistair’s commercial and financial experience to the Board of Cambridge Atomworks. His expertise and knowledge will be invaluable as Cambridge Atomworks continues its ambitious growth plans.” About Cambridge Atomworks Cambridge Atomworks was set up in January 2023 as a consulting partnership to develop the design of ODIN, a Transportable Nuclear Micro-Reactor using a low pressure coolant. In August 2023, Cambridge...
Nasdaq GlobeNewswire
30/10/2025

Intraoperative Radiation Therapy Market to Double by 2030 Driven by Precision…

Recent Industry Developments (2024–2025) Recent Industry Developments (2024–2025) Download PDF Brochure:https://www.datamintelligence.com/download-sample/intraoperative-radiation-therapy-market Browse in-depth TOC on "Intraoperative Radiation Therapy Market" 76 – Tables 69 – Figures 194 – Pages Growth Drivers: Precision Oncology Meets Surgical Efficiency The adoption of IORT is accelerating due to its proven ability to deliver concentrated radiation doses...
PR Newswire
30/10/2025

Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on October 30, 2025, at 11:00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on...
PR Newswire
30/10/2025

Novo Nordisk submits proposal to acquire Metsera, Inc.

Bagsværd, Denmark, 30 October 2025– Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity to maximise the potential of Metsera’s complementary portfolio and capabilities. An acquisition would be in line with Novo Nordisk’s long-term strategy of developing innovative and...
Nasdaq GlobeNewswire
30/10/2025

Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a…

Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "Chronic Urticaria is a disease where the burden on patients is often underestimated. ALY-301's ability to selectively target and deplete mast cells over other c-Kit positive cells, while potentially matching the efficacy…
PR Newswire
30/10/2025

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor…

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.The financing consists of an underwritten offering (the “Underwritten Offering”) of 4,691,358 ordinary shares and a registered direct offering to an investor of 740,740 ordinary...
Nasdaq GlobeNewswire
30/10/2025

Nippon Gases Targets Greater Resilience and Increased Uptime with Multi-Site…

Nippon Gases is one of the leading industrial and medical gases companies in Europe. Its operations cover the supply of gases – in various physical forms and purities – including oxygen, nitrogen, argon, carbon dioxide, hydrogen, helium, carbon monoxide, and the services and technologies associated with the use of gases and mixtures. Nippon Gases is one of the leading industrial and medical gases companies inEurope. Its operations cover the supply of gases – in various physical forms and...
PR Newswire
30/10/2025

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled“Harnessing Immune Plasticity to Alter the...
Nasdaq GlobeNewswire
30/10/2025

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare…

Leiden, the Netherlands, October 30, 2025:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025.Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Wednesday, November 19 at 10:00 GMT/11:00 CET. A live webcast and replay of the presentation can be found in the “Upcoming Events” and...
Nasdaq GlobeNewswire
30/10/2025

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a…

The licensed small molecule program aims to address significant unmet needs forautoimmune diseases . Programadds toBoehringer’s pipeline and its commitment to deliver breakthrough therapies for patients with inflammatory diseases . Ingelheim, Germany, and Tokyo, Japan ,[October 30 , 2025]–Boehringer Ingelheim and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and COO: Abdul Mullick) today announced that Boehringer Ingelheim has...
Nasdaq GlobeNewswire
30/10/2025

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial…

Financial Performance Financial Performance Year to date IDEFIRIX product sales totalled 143.6 MSEK and represented an increase of 29.1 MSEK or 25.4% compared to the same period a year ago (114.5 MSEK). Year to date product sales represent approximately 102% of total full-year product sales achieved in 2024. Product sales in the third quarter of 2025 totalled 30.1 MSEK, compared to 39.8 MSEK for the same period in 2024. Lower sales numbers in the third quarter are largely driven by...
PR Newswire
30/10/2025

Roche purchases shares in tender offer for 89bio, Inc

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 94,113,710 shares of 89bio’s common stock were validly tendered and not validly withdrawn in the tender offer (excluding shares tendered by notice of guaranteed delivery for which certificates have not yet been “received”), which represent approximately 60.49% of the total number of shares of 89bio’s common stock outstanding.Later today, Roche intends to complete the acquisition of 89bio...
Nasdaq GlobeNewswire
30/10/2025

QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards profitabilityAprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelinesOperating cash runway extended beyond profitability into 2028 following CHF 65...
Nasdaq GlobeNewswire
30/10/2025

Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its…

Additionally, this agreement strengthens ADCelerate™, Piramal's rapid, integrated approach to bioconjugate development and manufacture. Utilizing IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic. Additionally, this agreement strengthens ADCelerate™, Piramal's rapid, integrated approach to bioconjugate development and manufacture. Utilizing IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic...
PR Newswire
30/10/2025

ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal…

RSV is a leading cause of acute lower respiratory tract infections (ALRTI) in children under 5 years of age worldwide. More than 80% of children become infected before their first birthday, and nearly all have been exposed at age two. Among those infected, approximately one-third may develop severe ALRTI, such as bronchiolitis or pneumonia. Infants under one year of age, particularly preterm infants, are at greatest risk of developing serious RSV-related complications, often requiring…
PR Newswire
30/10/2025

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its…

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American...
Nasdaq GlobeNewswire
29/10/2025

Postoperative Ileus Market to Advance Moderately During the Forecast Period…

Postoperative Ileus Market Summary Postoperative Ileus Market Summary Discover the postoperative ileus new treatment @New Treatments for Postoperative Ileus Key Factors Driving the Growth of the Postoperative Ileus Market High Clinical and Economic Burden of Postoperative Ileus Postoperative ileus substantially increases length of stay, readmissions and per-patient hospital costs after abdominal and colorectal surgery, creating a strong financial incentive for...
PR Newswire
29/10/2025

Surgical Sutures Market to Reach USD 7,923.8 million by 2032, Growing At An…

Browse bthe report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/surgical-sutures-market Browse bthe report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/surgical-sutures-market Market Overview The Surgical Sutures Market comprises one of the most fundamental and widely used categories of medical devices. A surgical suture is a thread used to hold body tissues together after an...
PR Newswire
29/10/2025

Silver Wound Dressing Market to Reach USD 2,129.8 million by 2032, Growing At An…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/silver-wound-dressing-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/silver-wound-dressing-market Market Overview The Silver Wound Dressing Market encompasses a specialized category of advanced wound care products impregnated with elemental silver or a silver compound. These dressings are...
PR Newswire
29/10/2025

Sepsis Diagnostics Market to Reach USD 1,790.9 million by 2032, Growing At An…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/sepsis-diagnostics-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/sepsis-diagnostics-market Market Overview Sepsis is a life-threatening condition characterized by the body's dysregulated and extreme response to an infection, leading to organ dysfunction and failure. It is a medical emergency...
PR Newswire
29/10/2025

Digital Pathology Market Size to Surpass USD 6.55 Billion by 2035, Rising at a…

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/digital-pathology-market-1445/request-sample The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/digital-pathology-market-1445/request-sample Free Sample Includes: Why CXOs and Decision-Makers Should Prioritize Digital Pathology Technological and Market...
PR Newswire
29/10/2025

Hansa hosts call with distinguished transplant surgeons: Insights on clinical…

About Robert Montgomery, MD, PhD AboutRobert Montgomery, MD, PhD Dr.Robert Montgomeryis Chair of the Department of Surgery and Director of the NYU Langone Transplant Institute. As a pioneer and international expert in desensitization, he has taken part in numerous research studies, publications, and has received many awards for his work. Throughout his career, Dr. Montgomery has led innovation in transplantation, credited with developing and performing the first 'domino paired...
PR Newswire
29/10/2025

RAMSAY SANTE : availability of the Universal Registration Document 2025

PRESS RELEASE Paris, 29 thOctober 2025 AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT 2025 Ramsay Générale de Santé's 2025 Universal Registration Document was filed with the Autorité des marchés financiers (AMF) in ESEF format (European Single Electronic Format) on Wednesday 29 October 2025, under number D.25-0689. It is available to the public under the conditions provided for by the regulations in force; can be consulted on the Ramsay Santé website:...
Nasdaq GlobeNewswire
29/10/2025
Altri  Comunicati